Breast Cancer

Patricia Jakel, MN, RN, AOCN, shares how personal and professional experience impact her view on testing even beyond what is recommended.

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast cancer?

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

Dato-DXd has been given priority review for the treatment of patients with unresectable/metastatic triple-negative breast cancer.

Plus, a phase 1 breast cancer vaccine, updated NCCN guidelines, and a combination with standard-of-care potential in triple-negative breast cancer.

Destiny-Breast09 PROs demonstrated higher quality of life and fewer gastrointestinal symptoms in patients with HER2-positive advanced breast cancer.

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025.

Patient K.C. transitions from high-risk care to invasive mammary carcinoma treatment under the care and support of a breast cancer advanced practice provider.

Age and having had children were found to affect whether premenopausal women with breast cancer opted for fertility preservation.

Breast cancer survivors improved cognitive outcomes with both real and sham acupuncture, but real acupuncture showed greater gains.

Giredestrant displayed a safety profile consistent with prior findings and had a lower rate of discontinuation compared with standard endocrine therapy.

Frontline maintenance tucatinib plus trastuzumab and pertuzumab increased progression-free survival in patient with HER2-positive metastatic breast cancer.

A mobile health intervention was linked with an increase in general and cancer-specific QOL in adolescent and young adult breast cancer survivors.

Hormone replacement therapy was associated with a lower risk of developing BRCA1- or BRCA2-mutated breast cancer among those already at higher risk.

The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer.

Preoperative radiation and pembrolizumab improved T-cell infiltration in patients with higher-risk, HR-positive, HER2-negative, early-stage breast cancer.

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of progression-free survival.

Here are 5 presentations that oncology APPs should know about, from patient management to practice management.

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings.

Kristi Orbaugh, MSN, RNP, AOCN, AOCNP, shared the key toxicities of each CDK4/6 inhibitor and how to monitor for them.

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.